Intellia Therapeutics (NTLA) reported a Q1 net loss Monday of $0.81 per diluted share, narrowing from a loss of $1.10 a year earlier.
Analysts polled by FactSet expected a loss of $0.91.
Revenue for the quarter ended March 31 was $15 million, compared with $16.6 million a year earlier.
Analysts surveyed by FactSet expected $13.8 million.